DelistingAug 21, 2026, 04:29 PM
Silexion Therapeutics Receives Nasdaq Delisting Notice; Plans Appeal
AI Summary
Silexion Therapeutics Corp received a delisting notice from Nasdaq due to non-compliance with the minimum shareholders' equity requirement. The company reported shareholders' equity of $44,000 for the period ended June 30, 2026, falling short of the $2,500,000 minimum. Silexion intends to appeal the decision, but faces potential trading suspension and delisting if the appeal is unsuccessful.
Key Highlights
- Silexion Therapeutics Corp received a delisting notice from Nasdaq on August 18, 2026.
- The deficiency is due to non-compliance with the minimum shareholders' equity requirement ($2,500,000).
- Shareholders' equity was reported as $44,000 for the period ended June 30, 2026.
- The company intends to appeal the delisting determination before a Nasdaq Hearings Panel.
- Trading suspension and delisting would occur if the appeal is unsuccessful.
Price Impact
More from SLXN